Cybin: Researching Psychedelic Therapies for a Variety of Issues Using a Range of Delivery Methods

Related Posts

Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

Cybin files 13th provisional patent application focused on building up its telemedicine capabilities

VIDEO: Cybin (CYBN.NE) Completes 51st Pre-Clinical Psychedelic Molecule Study

VIDEO: Cybin (CYBN.NE) selects SAD and GAD as targets for their CYB004 psychedelic molecule

VIDEO: Cybin (CYBN.NE) files international patent application with Patent Cooperation Treaty (PCT)

VIDEO: Cybin (CYBN.NE) receives approval from IRB for CYB001 Phase II clinical trial

More on CYBN.NE

Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

Cybin files 13th provisional patent application focused on building up its telemedicine capabilities

VIDEO: Cybin (CYBN.NE) Completes 51st Pre-Clinical Psychedelic Molecule Study

VIDEO: Cybin (CYBN.NE) selects SAD and GAD as targets for their CYB004 psychedelic molecule

VIDEO: Cybin (CYBN.NE) files international patent application with Patent Cooperation Treaty (PCT)

VIDEO: Cybin (CYBN.NE) receives approval from IRB for CYB001 Phase II clinical trial